Clinical trials come up short again for Alphamab Oncology
The Chinese pharmaceutical firm has suffered its second clinical setback in a matter of weeks, after its U.S. partner halted trials of a sarcoma drug Key Takeaways: Alphamab Oncology could…
9966.HK
Recent Articles
RELATED ARTICLES
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
Discover hidden China stock gems in our weekly newsletter